Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AIM ImmunoTech Inc. Director's Dealing 2011

Mar 3, 2011

35334_dirs_2011-03-03_d6677f12-35cc-4f4d-932b-3b4d6eb244f2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2011-03-01

Reporting Person: Lander Russel J (VP of Process/QualityAssurance)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2011-03-01 Common Stock P 25000 $0.46 Acquired 182983 Direct
2011-03-01 Common Stock P 25000 $0.4595 Acquired 207983 Direct